A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
- A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
- 김인산; Junyoung Seo; Taslim A. Al-Hilal; Jun-Goo Jee; Yong-Lim Kim; Ha-Jeong Kim; Byung-Heon Lee; Soyoun Kim
- Issue Date
- VOL 14, NO 3-642
- The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting hemostatic clots. Here, we generated a double chambered short-length ferritin (sFt) construct that has an N-terminal region fused to multivalent clot targeting peptides (CLT: CNAGESSKNC) and a C-terminal end fused to a microplasmin (mu Pn); CLT recognizes fibrin-fibronectin complexes in clots, mu Pn efficiently dissolves clots, and the assembly of double chambered sFt (CLT-sFt-mu Pn) into nanocage structure protects the activated-mu Pn from its circulating inhibitors. Importantly, activated CLT-sFt-mu Pn thrombolytic nanocage showed a prolonged circulatory life over activated-mu Pn and efficiently lysed the preexisting clots in both arterial and venous thromboses models. Thus, CLT-sFt-mu Pn thrombolytic nanocage platform represents the prototype of a targeted clot-busting agent with high efficacy and safety over existing thrombolytic therapies.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.